

# Global Oligodendroglioma Treatment Market Growth 2022-2028

<https://marketpublishers.com/r/G6E778864EA0EN.html>

Date: January 2022

Pages: 118

Price: US\$ 3,660.00 (Single User License)

ID: G6E778864EA0EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Oligodendroglioma Treatment will have significant change from previous year. According to our (LP Information) latest study, the global Oligodendroglioma Treatment market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Oligodendroglioma Treatment market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Oligodendroglioma Treatment market is expected at value of US\$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Oligodendroglioma Treatment market, reaching US\$ million by the year 2028. As for the Europe Oligodendroglioma Treatment landscape, Germany is projected to reach US\$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Oligodendroglioma Treatment players cover AngioChem Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, and Cavion LLC, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Oligodendroglioma Treatment market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast

to 2028 in section 12.6

Alisertib

Bevacizumab

CDX-1401

Dasatinib

DCVax-L

IMA-950

Others

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Clinic

Hospital

ASCs

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

## APAC

China

Japan

Korea

Southeast Asia

India

Australia

## Europe

Germany

France

UK

Italy

Russia

## Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

AngioChem Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cavion LLC

Celldex Therapeutics Inc

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Immatics Biotechnologies GmbH

Ipsen SA

Leadiant Biosciences Inc

Millennium Pharmaceuticals Inc

Northwest Biotherapeutics Inc

Novartis AG

Pfizer Inc

Tocagen Inc

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Oligodendroglioma Treatment Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Oligodendroglioma Treatment by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Oligodendroglioma Treatment by Country/Region, 2017, 2022 & 2028

#### 2.2 Oligodendroglioma Treatment Segment by Type

- 2.2.1 Alisertib
- 2.2.2 Bevacizumab
- 2.2.3 CDX-1401
- 2.2.4 Dasatinib
- 2.2.5 DCVax-L
- 2.2.6 IMA-950
- 2.2.7 Others

#### 2.3 Oligodendroglioma Treatment Sales by Type

- 2.3.1 Global Oligodendroglioma Treatment Sales Market Share by Type (2017-2022)
- 2.3.2 Global Oligodendroglioma Treatment Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Oligodendroglioma Treatment Sale Price by Type (2017-2022)

#### 2.4 Oligodendroglioma Treatment Segment by Application

- 2.4.1 Clinic
- 2.4.2 Hospital
- 2.4.3 ASCs

#### 2.5 Oligodendroglioma Treatment Sales by Application

- 2.5.1 Global Oligodendroglioma Treatment Sale Market Share by Application

(2017-2022)

2.5.2 Global Oligodendroglioma Treatment Revenue and Market Share by Application

(2017-2022)

2.5.3 Global Oligodendroglioma Treatment Sale Price by Application (2017-2022)

### **3 GLOBAL OLIGODENDROGLIOMA TREATMENT BY COMPANY**

3.1 Global Oligodendroglioma Treatment Breakdown Data by Company

3.1.1 Global Oligodendroglioma Treatment Annual Sales by Company (2020-2022)

3.1.2 Global Oligodendroglioma Treatment Sales Market Share by Company

(2020-2022)

3.2 Global Oligodendroglioma Treatment Annual Revenue by Company (2020-2022)

3.2.1 Global Oligodendroglioma Treatment Revenue by Company (2020-2022)

3.2.2 Global Oligodendroglioma Treatment Revenue Market Share by Company

(2020-2022)

3.3 Global Oligodendroglioma Treatment Sale Price by Company

3.4 Key Manufacturers Oligodendroglioma Treatment Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Oligodendroglioma Treatment Product Location Distribution

3.4.2 Players Oligodendroglioma Treatment Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR OLIGODENDROGLIOMA TREATMENT BY GEOGRAPHIC REGION**

4.1 World Historic Oligodendroglioma Treatment Market Size by Geographic Region (2017-2022)

4.1.1 Global Oligodendroglioma Treatment Annual Sales by Geographic Region

(2017-2022)

4.1.2 Global Oligodendroglioma Treatment Annual Revenue by Geographic Region

4.2 World Historic Oligodendroglioma Treatment Market Size by Country/Region (2017-2022)

4.2.1 Global Oligodendroglioma Treatment Annual Sales by Country/Region

(2017-2022)

4.2.2 Global Oligodendroglioma Treatment Annual Revenue by Country/Region

- 4.3 Americas Oligodendroglioma Treatment Sales Growth
- 4.4 APAC Oligodendroglioma Treatment Sales Growth
- 4.5 Europe Oligodendroglioma Treatment Sales Growth
- 4.6 Middle East & Africa Oligodendroglioma Treatment Sales Growth

## **5 AMERICAS**

- 5.1 Americas Oligodendroglioma Treatment Sales by Country
  - 5.1.1 Americas Oligodendroglioma Treatment Sales by Country (2017-2022)
  - 5.1.2 Americas Oligodendroglioma Treatment Revenue by Country (2017-2022)
- 5.2 Americas Oligodendroglioma Treatment Sales by Type
- 5.3 Americas Oligodendroglioma Treatment Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

## **6 APAC**

- 6.1 APAC Oligodendroglioma Treatment Sales by Region
  - 6.1.1 APAC Oligodendroglioma Treatment Sales by Region (2017-2022)
  - 6.1.2 APAC Oligodendroglioma Treatment Revenue by Region (2017-2022)
- 6.2 APAC Oligodendroglioma Treatment Sales by Type
- 6.3 APAC Oligodendroglioma Treatment Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

## **7 EUROPE**

- 7.1 Europe Oligodendroglioma Treatment by Country
  - 7.1.1 Europe Oligodendroglioma Treatment Sales by Country (2017-2022)
  - 7.1.2 Europe Oligodendroglioma Treatment Revenue by Country (2017-2022)
- 7.2 Europe Oligodendroglioma Treatment Sales by Type
- 7.3 Europe Oligodendroglioma Treatment Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Oligodendroglioma Treatment by Country

8.1.1 Middle East & Africa Oligodendroglioma Treatment Sales by Country  
(2017-2022)

8.1.2 Middle East & Africa Oligodendroglioma Treatment Revenue by Country  
(2017-2022)

8.2 Middle East & Africa Oligodendroglioma Treatment Sales by Type

8.3 Middle East & Africa Oligodendroglioma Treatment Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Oligodendroglioma Treatment

10.3 Manufacturing Process Analysis of Oligodendroglioma Treatment

10.4 Industry Chain Structure of Oligodendroglioma Treatment

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels



11.2 Oligodendroglioma Treatment Distributors

11.3 Oligodendroglioma Treatment Customer

## **12 WORLD FORECAST REVIEW FOR OLIGODENDROGLIOMA TREATMENT BY GEOGRAPHIC REGION**

12.1 Global Oligodendroglioma Treatment Market Size Forecast by Region

12.1.1 Global Oligodendroglioma Treatment Forecast by Region (2023-2028)

12.1.2 Global Oligodendroglioma Treatment Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Oligodendroglioma Treatment Forecast by Type

12.7 Global Oligodendroglioma Treatment Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

13.1 AngioChem Inc

13.1.1 AngioChem Inc Company Information

13.1.2 AngioChem Inc Oligodendroglioma Treatment Product Offered

13.1.3 AngioChem Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 AngioChem Inc Main Business Overview

13.1.5 AngioChem Inc Latest Developments

13.2 Boehringer Ingelheim GmbH

13.2.1 Boehringer Ingelheim GmbH Company Information

13.2.2 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product Offered

13.2.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Boehringer Ingelheim GmbH Main Business Overview

13.2.5 Boehringer Ingelheim GmbH Latest Developments

13.3 Bristol-Myers Squibb Co

13.3.1 Bristol-Myers Squibb Co Company Information

13.3.2 Bristol-Myers Squibb Co Oligodendroglioma Treatment Product Offered

13.3.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Bristol-Myers Squibb Co Main Business Overview

- 13.3.5 Bristol-Myers Squibb Co Latest Developments
- 13.4 Cavion LLC
  - 13.4.1 Cavion LLC Company Information
  - 13.4.2 Cavion LLC Oligodendroglioma Treatment Product Offered
  - 13.4.3 Cavion LLC Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.4.4 Cavion LLC Main Business Overview
  - 13.4.5 Cavion LLC Latest Developments
- 13.5 Celldex Therapeutics Inc
  - 13.5.1 Celldex Therapeutics Inc Company Information
  - 13.5.2 Celldex Therapeutics Inc Oligodendroglioma Treatment Product Offered
  - 13.5.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.5.4 Celldex Therapeutics Inc Main Business Overview
  - 13.5.5 Celldex Therapeutics Inc Latest Developments
- 13.6 Eli Lilly and Co
  - 13.6.1 Eli Lilly and Co Company Information
  - 13.6.2 Eli Lilly and Co Oligodendroglioma Treatment Product Offered
  - 13.6.3 Eli Lilly and Co Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.6.4 Eli Lilly and Co Main Business Overview
  - 13.6.5 Eli Lilly and Co Latest Developments
- 13.7 F. Hoffmann-La Roche Ltd
  - 13.7.1 F. Hoffmann-La Roche Ltd Company Information
  - 13.7.2 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product Offered
  - 13.7.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.7.4 F. Hoffmann-La Roche Ltd Main Business Overview
  - 13.7.5 F. Hoffmann-La Roche Ltd Latest Developments
- 13.8 Immatics Biotechnologies GmbH
  - 13.8.1 Immatics Biotechnologies GmbH Company Information
  - 13.8.2 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product Offered
  - 13.8.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.8.4 Immatics Biotechnologies GmbH Main Business Overview
  - 13.8.5 Immatics Biotechnologies GmbH Latest Developments
- 13.9 Ipsen SA
  - 13.9.1 Ipsen SA Company Information
  - 13.9.2 Ipsen SA Oligodendroglioma Treatment Product Offered

13.9.3 Ipsen SA Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Ipsen SA Main Business Overview

13.9.5 Ipsen SA Latest Developments

13.10 Leadiant Biosciences Inc

13.10.1 Leadiant Biosciences Inc Company Information

13.10.2 Leadiant Biosciences Inc Oligodendroglioma Treatment Product Offered

13.10.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Leadiant Biosciences Inc Main Business Overview

13.10.5 Leadiant Biosciences Inc Latest Developments

13.11 Millennium Pharmaceuticals Inc

13.11.1 Millennium Pharmaceuticals Inc Company Information

13.11.2 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product Offered

13.11.3 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Millennium Pharmaceuticals Inc Main Business Overview

13.11.5 Millennium Pharmaceuticals Inc Latest Developments

13.12 Northwest Biotherapeutics Inc

13.12.1 Northwest Biotherapeutics Inc Company Information

13.12.2 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product Offered

13.12.3 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Northwest Biotherapeutics Inc Main Business Overview

13.12.5 Northwest Biotherapeutics Inc Latest Developments

13.13 Novartis AG

13.13.1 Novartis AG Company Information

13.13.2 Novartis AG Oligodendroglioma Treatment Product Offered

13.13.3 Novartis AG Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Novartis AG Main Business Overview

13.13.5 Novartis AG Latest Developments

13.14 Pfizer Inc

13.14.1 Pfizer Inc Company Information

13.14.2 Pfizer Inc Oligodendroglioma Treatment Product Offered

13.14.3 Pfizer Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Pfizer Inc Main Business Overview

13.14.5 Pfizer Inc Latest Developments

13.15 Tocagen Inc

13.15.1 Tocagen Inc Company Information

13.15.2 Tocagen Inc Oligodendroglioma Treatment Product Offered

13.15.3 Tocagen Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Tocagen Inc Main Business Overview

13.15.5 Tocagen Inc Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Oligodendroglioma Treatment Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Oligodendroglioma Treatment Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Alisertib

Table 4. Major Players of Bevacizumab

Table 5. Major Players of CDX-1401

Table 6. Major Players of Dasatinib

Table 7. Major Players of DCVax-L

Table 8. Major Players of IMA-950

Table 9. Major Players of Others

Table 10. Global Oligodendroglioma Treatment Sales by Type (2017-2022) & (K Pcs)

Table 11. Global Oligodendroglioma Treatment Sales Market Share by Type (2017-2022)

Table 12. Global Oligodendroglioma Treatment Revenue by Type (2017-2022) & (\$ million)

Table 13. Global Oligodendroglioma Treatment Revenue Market Share by Type (2017-2022)

Table 14. Global Oligodendroglioma Treatment Sale Price by Type (2017-2022) & (USD/Pcs)

Table 15. Global Oligodendroglioma Treatment Sales by Application (2017-2022) & (K Pcs)

Table 16. Global Oligodendroglioma Treatment Sales Market Share by Application (2017-2022)

Table 17. Global Oligodendroglioma Treatment Revenue by Application (2017-2022)

Table 18. Global Oligodendroglioma Treatment Revenue Market Share by Application (2017-2022)

Table 19. Global Oligodendroglioma Treatment Sale Price by Application (2017-2022) & (USD/Pcs)

Table 20. Global Oligodendroglioma Treatment Sales by Company (2020-2022) & (K Pcs)

Table 21. Global Oligodendroglioma Treatment Sales Market Share by Company (2020-2022)

Table 22. Global Oligodendroglioma Treatment Revenue by Company (2020-2022) (\$ Millions)

Table 23. Global Oligodendroglioma Treatment Revenue Market Share by Company (2020-2022)

Table 24. Global Oligodendroglioma Treatment Sale Price by Company (2020-2022) & (USD/Pcs)

Table 25. Key Manufacturers Oligodendroglioma Treatment Producing Area Distribution and Sales Area

Table 26. Players Oligodendroglioma Treatment Products Offered

Table 27. Oligodendroglioma Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 28. New Products and Potential Entrants

Table 29. Mergers & Acquisitions, Expansion

Table 30. Global Oligodendroglioma Treatment Sales by Geographic Region (2017-2022) & (K Pcs)

Table 31. Global Oligodendroglioma Treatment Sales Market Share Geographic Region (2017-2022)

Table 32. Global Oligodendroglioma Treatment Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 33. Global Oligodendroglioma Treatment Revenue Market Share by Geographic Region (2017-2022)

Table 34. Global Oligodendroglioma Treatment Sales by Country/Region (2017-2022) & (K Pcs)

Table 35. Global Oligodendroglioma Treatment Sales Market Share by Country/Region (2017-2022)

Table 36. Global Oligodendroglioma Treatment Revenue by Country/Region (2017-2022) & (\$ millions)

Table 37. Global Oligodendroglioma Treatment Revenue Market Share by Country/Region (2017-2022)

Table 38. Americas Oligodendroglioma Treatment Sales by Country (2017-2022) & (K Pcs)

Table 39. Americas Oligodendroglioma Treatment Sales Market Share by Country (2017-2022)

Table 40. Americas Oligodendroglioma Treatment Revenue by Country (2017-2022) & (\$ Millions)

Table 41. Americas Oligodendroglioma Treatment Revenue Market Share by Country (2017-2022)

Table 42. Americas Oligodendroglioma Treatment Sales by Type (2017-2022) & (K Pcs)

Table 43. Americas Oligodendroglioma Treatment Sales Market Share by Type (2017-2022)

Table 44. Americas Oligodendroglioma Treatment Sales by Application (2017-2022) &



(K Pcs)

Table 45. Americas Oligodendroglioma Treatment Sales Market Share by Application (2017-2022)

Table 46. APAC Oligodendroglioma Treatment Sales by Region (2017-2022) & (K Pcs)

Table 47. APAC Oligodendroglioma Treatment Sales Market Share by Region (2017-2022)

Table 48. APAC Oligodendroglioma Treatment Revenue by Region (2017-2022) & (\$ Millions)

Table 49. APAC Oligodendroglioma Treatment Revenue Market Share by Region (2017-2022)

Table 50. APAC Oligodendroglioma Treatment Sales by Type (2017-2022) & (K Pcs)

Table 51. APAC Oligodendroglioma Treatment Sales Market Share by Type (2017-2022)

Table 52. APAC Oligodendroglioma Treatment Sales by Application (2017-2022) & (K Pcs)

Table 53. APAC Oligodendroglioma Treatment Sales Market Share by Application (2017-2022)

Table 54. Europe Oligodendroglioma Treatment Sales by Country (2017-2022) & (K Pcs)

Table 55. Europe Oligodendroglioma Treatment Sales Market Share by Country (2017-2022)

Table 56. Europe Oligodendroglioma Treatment Revenue by Country (2017-2022) & (\$ Millions)

Table 57. Europe Oligodendroglioma Treatment Revenue Market Share by Country (2017-2022)

Table 58. Europe Oligodendroglioma Treatment Sales by Type (2017-2022) & (K Pcs)

Table 59. Europe Oligodendroglioma Treatment Sales Market Share by Type (2017-2022)

Table 60. Europe Oligodendroglioma Treatment Sales by Application (2017-2022) & (K Pcs)

Table 61. Europe Oligodendroglioma Treatment Sales Market Share by Application (2017-2022)

Table 62. Middle East & Africa Oligodendroglioma Treatment Sales by Country (2017-2022) & (K Pcs)

Table 63. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Country (2017-2022)

Table 64. Middle East & Africa Oligodendroglioma Treatment Revenue by Country (2017-2022) & (\$ Millions)

Table 65. Middle East & Africa Oligodendroglioma Treatment Revenue Market Share by

Country (2017-2022)

Table 66. Middle East & Africa Oligodendroglioma Treatment Sales by Type (2017-2022) & (K Pcs)

Table 67. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Type (2017-2022)

Table 68. Middle East & Africa Oligodendroglioma Treatment Sales by Application (2017-2022) & (K Pcs)

Table 69. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Application (2017-2022)

Table 70. Key Market Drivers & Growth Opportunities of Oligodendroglioma Treatment

Table 71. Key Market Challenges & Risks of Oligodendroglioma Treatment

Table 72. Key Industry Trends of Oligodendroglioma Treatment

Table 73. Oligodendroglioma Treatment Raw Material

Table 74. Key Suppliers of Raw Materials

Table 75. Oligodendroglioma Treatment Distributors List

Table 76. Oligodendroglioma Treatment Customer List

Table 77. Global Oligodendroglioma Treatment Sales Forecast by Region (2023-2028) & (K Pcs)

Table 78. Global Oligodendroglioma Treatment Sales Market Forecast by Region

Table 79. Global Oligodendroglioma Treatment Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 80. Global Oligodendroglioma Treatment Revenue Market Share Forecast by Region (2023-2028)

Table 81. Americas Oligodendroglioma Treatment Sales Forecast by Country (2023-2028) & (K Pcs)

Table 82. Americas Oligodendroglioma Treatment Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 83. APAC Oligodendroglioma Treatment Sales Forecast by Region (2023-2028) & (K Pcs)

Table 84. APAC Oligodendroglioma Treatment Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 85. Europe Oligodendroglioma Treatment Sales Forecast by Country (2023-2028) & (K Pcs)

Table 86. Europe Oligodendroglioma Treatment Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 87. Middle East & Africa Oligodendroglioma Treatment Sales Forecast by Country (2023-2028) & (K Pcs)

Table 88. Middle East & Africa Oligodendroglioma Treatment Revenue Forecast by Country (2023-2028) & (\$ millions)



Table 89. Global Oligodendroglioma Treatment Sales Forecast by Type (2023-2028) & (K Pcs)

Table 90. Global Oligodendroglioma Treatment Sales Market Share Forecast by Type (2023-2028)

Table 91. Global Oligodendroglioma Treatment Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 92. Global Oligodendroglioma Treatment Revenue Market Share Forecast by Type (2023-2028)

Table 93. Global Oligodendroglioma Treatment Sales Forecast by Application (2023-2028) & (K Pcs)

Table 94. Global Oligodendroglioma Treatment Sales Market Share Forecast by Application (2023-2028)

Table 95. Global Oligodendroglioma Treatment Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 96. Global Oligodendroglioma Treatment Revenue Market Share Forecast by Application (2023-2028)

Table 97. AngioChem Inc Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 98. AngioChem Inc Oligodendroglioma Treatment Product Offered

Table 99. AngioChem Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 100. AngioChem Inc Main Business

Table 101. AngioChem Inc Latest Developments

Table 102. Boehringer Ingelheim GmbH Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 103. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product Offered

Table 104. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 105. Boehringer Ingelheim GmbH Main Business

Table 106. Boehringer Ingelheim GmbH Latest Developments

Table 107. Bristol-Myers Squibb Co Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 108. Bristol-Myers Squibb Co Oligodendroglioma Treatment Product Offered

Table 109. Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 110. Bristol-Myers Squibb Co Main Business

Table 111. Bristol-Myers Squibb Co Latest Developments

Table 112. Cavion LLC Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 113. Cavion LLC Oligodendroglioma Treatment Product Offered

Table 114. Cavion LLC Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 115. Cavion LLC Main Business

Table 116. Cavion LLC Latest Developments

Table 117. Celldex Therapeutics Inc Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 118. Celldex Therapeutics Inc Oligodendroglioma Treatment Product Offered

Table 119. Celldex Therapeutics Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 120. Celldex Therapeutics Inc Main Business

Table 121. Celldex Therapeutics Inc Latest Developments

Table 122. Eli Lilly and Co Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 123. Eli Lilly and Co Oligodendroglioma Treatment Product Offered

Table 124. Eli Lilly and Co Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 125. Eli Lilly and Co Main Business

Table 126. Eli Lilly and Co Latest Developments

Table 127. F. Hoffmann-La Roche Ltd Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 128. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product Offered

Table 129. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 130. F. Hoffmann-La Roche Ltd Main Business

Table 131. F. Hoffmann-La Roche Ltd Latest Developments

Table 132. Immatix Biotechnologies GmbH Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 133. Immatix Biotechnologies GmbH Oligodendroglioma Treatment Product Offered

Table 134. Immatix Biotechnologies GmbH Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 135. Immatix Biotechnologies GmbH Main Business

Table 136. Immatix Biotechnologies GmbH Latest Developments

Table 137. Ipsen SA Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 138. Ipsen SA Oligodendroglioma Treatment Product Offered

Table 139. Ipsen SA Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 140. Ipsen SA Main Business

Table 141. Ipsen SA Latest Developments

Table 142. Leadiant Biosciences Inc Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 143. Leadiant Biosciences Inc Oligodendroglioma Treatment Product Offered

Table 144. Leadiant Biosciences Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 145. Leadiant Biosciences Inc Main Business

Table 146. Leadiant Biosciences Inc Latest Developments

Table 147. Millennium Pharmaceuticals Inc Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 148. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product Offered

Table 149. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 150. Millennium Pharmaceuticals Inc Main Business

Table 151. Millennium Pharmaceuticals Inc Latest Developments

Table 152. Northwest Biotherapeutics Inc Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 153. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product Offered

Table 154. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 155. Northwest Biotherapeutics Inc Main Business

Table 156. Northwest Biotherapeutics Inc Latest Developments

Table 157. Novartis AG Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 158. Novartis AG Oligodendroglioma Treatment Product Offered

Table 159. Novartis AG Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 160. Novartis AG Main Business

Table 161. Novartis AG Latest Developments

Table 162. Pfizer Inc Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 163. Pfizer Inc Oligodendroglioma Treatment Product Offered

Table 164. Pfizer Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 165. Pfizer Inc Main Business

Table 166. Pfizer Inc Latest Developments

Table 167. Tocagen Inc Basic Information, Oligodendroglioma Treatment Manufacturing Base, Sales Area and Its Competitors

Table 168. Tocagen Inc Oligodendroglioma Treatment Product Offered

Table 169. Tocagen Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 170. Tocagen Inc Main Business

Table 171. Tocagen Inc Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Oligodendroglioma Treatment
- Figure 2. Oligodendroglioma Treatment Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Oligodendroglioma Treatment Sales Growth Rate 2017-2028 (K Pcs)
- Figure 7. Global Oligodendroglioma Treatment Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Oligodendroglioma Treatment Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Alisertib
- Figure 10. Product Picture of Bevacizumab
- Figure 11. Product Picture of CDX-1401
- Figure 12. Product Picture of Dasatinib
- Figure 13. Product Picture of DCVax-L
- Figure 14. Product Picture of IMA-950
- Figure 15. Product Picture of Others
- Figure 16. Global Oligodendroglioma Treatment Sales Market Share by Type in 2021
- Figure 17. Global Oligodendroglioma Treatment Revenue Market Share by Type (2017-2022)
- Figure 18. Oligodendroglioma Treatment Consumed in Clinic
- Figure 19. Global Oligodendroglioma Treatment Market: Clinic (2017-2022) & (K Pcs)
- Figure 20. Oligodendroglioma Treatment Consumed in Hospital
- Figure 21. Global Oligodendroglioma Treatment Market: Hospital (2017-2022) & (K Pcs)
- Figure 22. Oligodendroglioma Treatment Consumed in ASCs
- Figure 23. Global Oligodendroglioma Treatment Market: ASCs (2017-2022) & (K Pcs)
- Figure 24. Global Oligodendroglioma Treatment Sales Market Share by Application (2017-2022)
- Figure 25. Global Oligodendroglioma Treatment Revenue Market Share by Application in 2021
- Figure 26. Oligodendroglioma Treatment Revenue Market by Company in 2021 (\$ Million)
- Figure 27. Global Oligodendroglioma Treatment Revenue Market Share by Company in 2021
- Figure 28. Global Oligodendroglioma Treatment Sales Market Share by Geographic Region (2017-2022)

Figure 29. Global Oligodendroglioma Treatment Revenue Market Share by Geographic Region in 2021

Figure 30. Global Oligodendroglioma Treatment Sales Market Share by Region (2017-2022)

Figure 31. Global Oligodendroglioma Treatment Revenue Market Share by Country/Region in 2021

Figure 32. Americas Oligodendroglioma Treatment Sales 2017-2022 (K Pcs)

Figure 33. Americas Oligodendroglioma Treatment Revenue 2017-2022 (\$ Millions)

Figure 34. APAC Oligodendroglioma Treatment Sales 2017-2022 (K Pcs)

Figure 35. APAC Oligodendroglioma Treatment Revenue 2017-2022 (\$ Millions)

Figure 36. Europe Oligodendroglioma Treatment Sales 2017-2022 (K Pcs)

Figure 37. Europe Oligodendroglioma Treatment Revenue 2017-2022 (\$ Millions)

Figure 38. Middle East & Africa Oligodendroglioma Treatment Sales 2017-2022 (K Pcs)

Figure 39. Middle East & Africa Oligodendroglioma Treatment Revenue 2017-2022 (\$ Millions)

Figure 40. Americas Oligodendroglioma Treatment Sales Market Share by Country in 2021

Figure 41. Americas Oligodendroglioma Treatment Revenue Market Share by Country in 2021

Figure 42. United States Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 43. Canada Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 44. Mexico Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 45. Brazil Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 46. APAC Oligodendroglioma Treatment Sales Market Share by Region in 2021

Figure 47. APAC Oligodendroglioma Treatment Revenue Market Share by Regions in 2021

Figure 48. China Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 49. Japan Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 50. South Korea Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 51. Southeast Asia Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 52. India Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 53. Australia Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 54. Europe Oligodendroglioma Treatment Sales Market Share by Country in



2021

Figure 55. Europe Oligodendroglioma Treatment Revenue Market Share by Country in 2021

Figure 56. Germany Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 57. France Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 58. UK Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 59. Italy Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 60. Russia Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 61. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Country in 2021

Figure 62. Middle East & Africa Oligodendroglioma Treatment Revenue Market Share by Country in 2021

Figure 63. Egypt Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 64. South Africa Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 65. Israel Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 66. Turkey Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 67. GCC Country Oligodendroglioma Treatment Revenue Growth 2017-2022 (\$ Millions)

Figure 68. Manufacturing Cost Structure Analysis of Oligodendroglioma Treatment in 2021

Figure 69. Manufacturing Process Analysis of Oligodendroglioma Treatment

Figure 70. Industry Chain Structure of Oligodendroglioma Treatment

Figure 71. Channels of Distribution

Figure 72. Distributors Profiles

## I would like to order

Product name: Global Oligodendroglioma Treatment Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/G6E778864EA0EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6E778864EA0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970